» Articles » PMID: 34932136

Advanced Liver Fibrosis Measured by Transient Elastography Predicts Chronic Kidney Disease Development in Individuals with Non-alcoholic Fatty Liver Disease

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2021 Dec 21
PMID 34932136
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: Non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) are progressive chronic conditions that share important cardiometabolic risk factors and pathogenic mechanisms. We investigated the association between liver fibrosis measured by transient elastography (TE) and the risk of incident CKD in individuals with NAFLD.

Methods: A total of 5983 participants with NAFLD (defined as controlled attenuation parameter >222 dB/m) but without CKD who underwent TE between March 2012 and August 2018 were selected. The primary outcome was incident CKD, defined as the occurrence of eGFR <60 ml min [1.73 m] or proteinuria (≥1+ on dipstick test) on two consecutive measurements during follow-up. The secondary outcome was a 25% decline in eGFR measured on two consecutive visits.

Results: The mean age was 51.8 years and 3756 (62.8%) participants were male. During 17,801 person-years of follow-up (mean follow-up of 3.0 years), 62 participants (1.0%) developed incident CKD. When stratified into TE-defined fibrosis stages (F0-F4), multivariable Cox models revealed that risk of incident CKD was 5.40-fold (95% CI 2.46, 11.84; p < 0.001) higher in the F3/F4 group (≥9.5 kPa) than in the F0 group (<5.5 kPa). During 17,577 person-years of follow-up (mean follow-up of 3.0 years), 201 participants (3.4%) experienced the secondary outcome, for which the F3/F4 group had a 3.22-fold higher risk (95% CI 1.96, 5.28; p < 0.001) than the F0 group.

Conclusions/interpretation: In this large cohort of individuals with NAFLD but without baseline CKD, advanced liver fibrosis measured by TE was significantly associated with a higher risk of incident CKD.

Citing Articles

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.

Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C Hepatol Int. 2025; .

PMID: 40016576 DOI: 10.1007/s12072-024-10774-3.


Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis.

Zhou J, Sun D, Targher G, Byrne C, Lee B, Hamaguchi M eGastroenterology. 2025; 1(1):e100005.

PMID: 39944252 PMC: 11770460. DOI: 10.1136/egastro-2023-100005.


Bioactive metabolites: A clue to the link between MASLD and CKD?.

Chen W, Zhang J, Chen L, Byrne C, Targher G, Luo L Clin Mol Hepatol. 2024; 31(1):56-73.

PMID: 39428978 PMC: 11791555. DOI: 10.3350/cmh.2024.0782.


Interactions between Multiple Organs and Nutritional Metabolism in the Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Yoneda M, Nakajima A Nutrients. 2023; 15(23).

PMID: 38068768 PMC: 10708086. DOI: 10.3390/nu15234910.


Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care.

Yoneda M, Kobayashi T, Iwaki M, Nogami A, Saito S, Nakajima A Gut Liver. 2023; 17(6):843-852.

PMID: 37560797 PMC: 10651384. DOI: 10.5009/gnl220545.


References
1.
Bellentani S . The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017; 37 Suppl 1:81-84. DOI: 10.1111/liv.13299. View

2.
Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

3.
Yoo J, Kim W, Kim M, Won Jun D, Kim S, Yeon J . Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol. 2018; 25(1):1-11. PMC: 6435971. DOI: 10.3350/cmh.2018.0037. View

4.
Byrne C, Targher G . NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl):S47-64. DOI: 10.1016/j.jhep.2014.12.012. View

5.
Ikejima K, Kon K, Yamashina S . Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights. Clin Mol Hepatol. 2020; 26(4):728-735. PMC: 7641569. DOI: 10.3350/cmh.2020.0202. View